Justin MacDonald - Arch Biopartners CoFounder Scientist

All Insiders Canada . 
Stock . Arch Biopartners . Stakeholders . Insider . Justin MacDonald
ARCH Stock  CAD 1.95  0.01  0.51%   

Insider

Justin MacDonald is CoFounder Scientist of Arch Biopartners
Address 27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5
Phone647 428 7031
Webhttps://www.archbiopartners.com

Arch Biopartners Management Efficiency

The company has return on total asset (ROA) of (0.812) % which means that it has lost $0.812 on every $100 spent on assets. This is way below average. Arch Biopartners' management efficiency ratios could be used to measure how well Arch Biopartners manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 14.13 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (2.8 K). At this time, Arch Biopartners' Total Current Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to climb to 0.32 in 2024, whereas Other Current Assets are likely to drop slightly above 39.8 K in 2024.
Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Heather PhillipsNanalysis Scientific Corp
N/A
Merle BoonPerimeter Medical Imaging
N/A
MBBS MDMedicenna Therapeutics Corp
N/A
Steve SapotPerimeter Medical Imaging
N/A
Christopher ScottPerimeter Medical Imaging
54
Samuel MDMedicenna Therapeutics Corp
N/A
Greg McFeetorsNanalysis Scientific Corp
N/A
Brian McAlisterNervGen Pharma Corp
N/A
Julien MullerNanalysis Scientific Corp
N/A
Sean MScNanalysis Scientific Corp
54
Jeremy SobottaPerimeter Medical Imaging
N/A
Susanne RiegelNanalysis Scientific Corp
N/A
Matt ZamoraNanalysis Scientific Corp
N/A
Rochelle KeenPerimeter Medical Imaging
N/A
Adam MDNervGen Pharma Corp
N/A
Vladimir PekarPerimeter Medical Imaging
N/A
Fahar MerchantMedicenna Therapeutics Corp
67
Harold DMDNervGen Pharma Corp
N/A
Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. ARCH BIOPARTNERS is traded on TSX Venture Exchange in Canada. Arch Biopartners (ARCH) is traded on TSX Venture Exchange in Canada and employs 7 people. Arch Biopartners is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Asset-0.81

Arch Biopartners Leadership Team

Elected by the shareholders, the Arch Biopartners' board of directors comprises two types of representatives: Arch Biopartners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Biopartners' management team and ensure that shareholders' interests are well served. Arch Biopartners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Biopartners' outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel MD, Chief CoFounder
Andrew CFA, Acting Director
Daniel Muruve, Chief Science Officer
Paul Beck, CoFounder Scientist
Aaron Benson, Director Communications
Richard Muruve, President CEO, Director
Justin MacDonald, CoFounder Scientist

Arch Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arch Biopartners a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.81
Profit Margin(1.86) %
Operating Margin(1.39) %
Current Valuation132.23 M
Shares Outstanding64.94 M
Shares Owned By Insiders19.86 %
Number Of Shares Shorted3.97 K
Price To Sales91.52 X
Revenue1.98 M
Gross Profit(502.88 K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arch Stock Analysis

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY